TLR3 Serves as a Prognostic Biomarker and Associates with Immune Infiltration in the Renal Clear Cell Carcinoma Microenvironment

Figure 7

The mRNA expression of TLR3 in subgroups of patients with KIRC (UALCAN). (a) TLR3 expression in normal and KIRC (Caucasian, African-American, or Asian) samples. (b) TLR3 expression in normal and KIRC (male or female) samples. (c) TLR3 expression in normal and KIRC (21–40, 41–60, 61–80, or 81–100 years old) samples. (d) TLR3 expression in normal and KIRC (ccA subtype or ccB subtype) samples. (e) TLR3 expression in normal and KIRC (Grades 1, 2, 3, or 4) samples. (f) TLR3 expression in normal and KIRC (Stages 1, 2, 3, or 4) samples. (g) TLR3 expression in normal and KIRC (with or without nodal metastasis) samples. Data are mean ± SE. ; ; . The difference of TLR3 mRNA expression among groups was analyzed with the rank-sum test using the TCGA KIRC data set (N = 537).

(a)

(b)

(c)

(d)

(e)

(f)

(g)